Monday, October 15, 2018
 
 
Company News: Page (1) of 1 - 10/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
 
(October 12, 2018)

OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf, Germany).

The presentations are:

Therapeutic efficacy of 177Lu-lilotomab satetraxetan in non-Hodgkin B-cell Lymphoma is controlled by G2/M cell cycle progression



Authors:  A. Pichard et al.
Session: 305 - M2M: Therapy Effects, Preclinical
Abstract No. OP-069
Format: Oral presentation

Date/time: Sunday 14 October, 11:30-12:45 CEST

Tumor Absorbed Dose and Changes in FDG PET Parameters in Non-Hodgkin Lymphoma Patients Treated with 177Lu-lilotomab satetraxetan

Authors: A. Løndalen et al.
Session: 608 - Clinical Oncology - Rapid Fire Session: It´s in the Blood!
Abstract No. OP-252
Format: Oral presentation

Date/time: Monday 15 October, 08:00-09:30 CEST

Abstracts are available by clicking here clicking here

For further information, please contact:

IR enquiries

Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medici,c2642692

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medicine-eanm-300730074.html

SOURCE Nordic Nanovector

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Pro AV,Presentors,Business Issues,Presentation,Marketing,Corporate/Company,Science,Lifestyle,Medical,Cancer,
Related Sites: Digital Producer ,   Audio Video Producer ,   Presentation Master ,   Oceania ,   DMN Newswire ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: DMN Newsletter ,   CMN Newsletter ,   KNews Newsletter ,   Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines